519 related articles for article (PubMed ID: 24747753)
1. Antidepressant and anti-anxiety like effects of 4i (N-(3-chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT3 receptor antagonist in acute and chronic neurobehavioral rodent models.
Gupta D; Radhakrishnan M; Thangaraj D; Kurhe Y
Eur J Pharmacol; 2014 Jul; 735():59-67. PubMed ID: 24747753
[TBL] [Abstract][Full Text] [Related]
2. A novel 5HT3 antagonist 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide) prevents diabetes-induced depressive phenotypes in mice: Modulation of serotonergic system.
Gupta D; Thangaraj D; Radhakrishnan M
Behav Brain Res; 2016 Jan; 297():41-50. PubMed ID: 26454237
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant-like effects of a novel 5-HT3 receptor antagonist 6z in acute and chronic murine models of depression.
Gupta D; Radhakrishnan M; Kurhe Y; Thangaraj D; Prabhakar V; Kanade P
Acta Pharmacol Sin; 2014 Dec; 35(12):1493-503. PubMed ID: 25418380
[TBL] [Abstract][Full Text] [Related]
4. Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system.
Gupta D; Radhakrishnan M; Kurhe Y
Eur J Pharmacol; 2014 Dec; 744():59-66. PubMed ID: 25284215
[TBL] [Abstract][Full Text] [Related]
5. Anti-depressant like activity of N-n-butyl-3-methoxyquinoxaline-2-carboxamide (6o) a 5-HT3 receptor antagonist.
Bhatt S; Mahesh R; Devadoss T; Jindal A
Indian J Exp Biol; 2013 Jun; 51(6):435-43. PubMed ID: 23926691
[TBL] [Abstract][Full Text] [Related]
6. Neuropharmacological and neurochemical evaluation of N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n): a novel serotonergic 5-HT3 receptor antagonist for co-morbid antidepressant- and anxiolytic-like potential using traumatic brain injury model in rats.
Bhatt S; Mahesh R; Jindal A; Devadoss T
J Basic Clin Physiol Pharmacol; 2017 Mar; 28(2):93-100. PubMed ID: 27662644
[TBL] [Abstract][Full Text] [Related]
7. Anti-depressant-like activity of a novel serotonin type-3 (5-HT3) receptor antagonist in rodent models of depression.
Gupta D; Devadoss T; Bhatt S; Gautam B; Jindal A; Pandey D; Mahesh R
Indian J Exp Biol; 2011 Aug; 49(8):619-26. PubMed ID: 21870430
[TBL] [Abstract][Full Text] [Related]
8. Protective effects of a novel 5-HT3 receptor antagonist, N-n-butyl-3-methoxy quinoxaline-2-carboxamide (6o) against chronic unpredictable mild stress-induced behavioral changes and biochemical alterations.
Bhatt S; Mahesh R; Jindal A; Devadoss T
Pharmacol Biochem Behav; 2014 Jul; 122():234-9. PubMed ID: 24769308
[TBL] [Abstract][Full Text] [Related]
9. Effect of a novel 5-HT3 receptor antagonist 4i, in corticosterone-induced depression-like behavior and oxidative stress in mice.
Gupta D; Radhakrishnan M; Kurhe Y
Steroids; 2015 Apr; 96():95-102. PubMed ID: 25668613
[TBL] [Abstract][Full Text] [Related]
10. Antidepressant & anxiolytic activities of N-(pyridin-3-yl) quinoxalin-2-carboxamide: A novel serotonin type 3 receptor antagonist in behavioural animal models.
Pandey DK; Devadoss T; Modak N; Mahesh R
Indian J Med Res; 2016 Oct; 144(4):614-621. PubMed ID: 28256473
[TBL] [Abstract][Full Text] [Related]
11. Antidepressant-like effect of novel 5-HT3 receptor antagonist N-n-butyl-3-ethoxyquinoxalin-2-carboxamide (6p): an approach using rodent behavioral antidepressant tests.
Bhatt S; Mahesh R; Devadoss T; Jindal AK
Indian J Pharmacol; 2013; 45(4):348-53. PubMed ID: 24014909
[TBL] [Abstract][Full Text] [Related]
12. Antidepressant and anxiolytic-like effects of 4n, a novel 5-HT3 receptor antagonist using behaviour based rodent models.
Kumar B; Jindal A; Pandey DK; Bhatt S; Devadoss T; Mahesh R
Indian J Exp Biol; 2012 Sep; 50(9):625-32. PubMed ID: 23140020
[TBL] [Abstract][Full Text] [Related]
13. QCM-4, a serotonergic type 3 receptor modulator attenuates depression co-morbid with obesity in mice: an approach based on behavioral and biochemical investigations.
Kurhe Y; Mahesh R; Gupta D; Devadoss T
Eur J Pharmacol; 2014 Oct; 740():611-8. PubMed ID: 24973694
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and pharmacological evaluation of novel 2-(4-substituted piperazin-1-yl)1, 8 naphthyridine 3-carboxylic acids as 5-HT3 receptor antagonists for the management of depression.
Dhar AK; Mahesh R; Jindal A; Devadoss T; Bhatt S
Chem Biol Drug Des; 2014 Dec; 84(6):721-31. PubMed ID: 24903617
[TBL] [Abstract][Full Text] [Related]
15. QCM-4 a novel 5-HT3 antagonist attenuates the behavioral and biochemical alterations on chronic unpredictable mild stress model of depression in Swiss albino mice.
Kurhe Y; Radhakrishnan M; Gupta D; Devadoss T
J Pharm Pharmacol; 2014 Jan; 66(1):122-32. PubMed ID: 24180368
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of antidepressant activity of novel 2-methoxy 1, 8 naphthyridine 3-carboxamides as 5-HT3 receptor antagonists.
Mahesh R; Dhar AK; Jindal A; Bhatt S
Chem Biol Drug Des; 2014 May; 83(5):583-91. PubMed ID: 24330585
[TBL] [Abstract][Full Text] [Related]
17. QCM-4, a 5-HT₃ receptor antagonist ameliorates plasma HPA axis hyperactivity, leptin resistance and brain oxidative stress in depression and anxiety-like behavior in obese mice.
Kurhe Y; Mahesh R; Devadoss T
Biochem Biophys Res Commun; 2015 Jan; 456(1):74-9. PubMed ID: 25446100
[TBL] [Abstract][Full Text] [Related]
18. 2-(4-substituted piperazin-1-yl)-1,8-naphthyridine-3-carboxylic acids: novel 5-HT3 receptor antagonists with anxiolytic-like activity in rodent behavioral models.
Mahesh R; Dhar AK; Jindal A; Bhatt S
Can J Physiol Pharmacol; 2013 Oct; 91(10):848-54. PubMed ID: 24144056
[TBL] [Abstract][Full Text] [Related]
19. Piperazine analogs of naphthyridine-3-carboxamides and indole-2-carboxamides: novel 5-HT3 receptor antagonists with antidepressant-like activity.
Dhar AK; Mahesh R; Jindal A; Bhatt S
Arch Pharm (Weinheim); 2015 Jan; 348(1):34-45. PubMed ID: 25581677
[TBL] [Abstract][Full Text] [Related]
20. Neuropharmacological evaluation of a novel 5-HT3 receptor antagonist (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl) methanone (6g) on lipopolysaccharide-induced anxiety models in mice.
Bhatt S; Mahesh R; Devadoss T; Jindal A
J Basic Clin Physiol Pharmacol; 2017 Mar; 28(2):101-106. PubMed ID: 27664773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
